Many clinicians are not sure what constitutes clinically relevant haematuria; they are also unsure about when patients with haematuria should be referred for specialist assessment and whether they should be referred to a urologist, nephrologist, or both.
In 2006 the National Institute for Health Research, Health Technology Assessment (NIHR HTA) commissioned a systematic review of the evidence for the investigation of microscopic haematuria, with a view to developing an algorithm for assessing patients in primary care.
1 They concluded that, "Given the paucity of evidence . . . it is not possible to derive an algorithm of the diagnostic pathway for haematuria that would be solely supported by existing evidence." None the less, the investigation of microscopic haematuria is important because serious underlying conditions are present in a proportion of patients.
In the absence of definitive evidence, guidelines based on consensus agreement and expert opinion would be useful and have been proposed. 3 4 However, the terminology and definitions used have not been standardised, so the appropriate baseline assessment of patients is still unclear. In this review, we discuss the rationale for introducing the terms "visible haematuria" and "non-visible haematuria" (symptomatic and asymptomatic) (box 1). The figure shows an algorithm for the assessment of patients with nonvisible haematuria.
What causes non-visible haematuria?
The presence of non-visible blood in the urine can have a transient or spurious cause; if it persists it may indicate underlying pathology.
Causes of transient non-visible haematuria
The causes of transient non-visible haematuria should be considered and excluded before further assessment (box 2). Transient non-visible haematuria is commonly associated with urinary tract infection, and a repeat dipstick test after treatment for infection will determine whether haematuria is persistent. Urinary tract infection can be the first presentation of important urinary pathology, so recurrent infections are an indication for further investigation, regardless of haematuria. 5 6 Observational studies in athletes confirm that repeated foot striking, such as in long distance running, can cause haematuria, 7 and urine testing should be repeated at least three days after such activity.
Spurious causes
Menstruation can lead to urinary contamination with erythrocytes, so testing when menstruation has ended is recommended. Discoloration of urine (by drugs or foods) and myoglobin released from necrotic muscle cells (rhabdomyolysis) are other considerations when haematuria is detected on dipstick testing. 8 Causes of persistent non-visible haematuria Persistent non-visible haematuria can have urological or nephrological causes (box 3). The most important urological causes include cancer and calculus disease, which are seen in about 5% and 8% of patients, respectively. 9 10 Urothelial cell carcinoma is the most common cancer detected. It is present in about 4% of cases overall but is more prevalent in males and increases with age to 10% in men over 60 with risk factors for disease. 9 10 In young people (<40 years), especially young females, cancer is an uncommon cause of asymptomatic non-visible haematuria, and a glomerular cause is more likely. It is unclear what proportion of patients with haematuria have nephrological as opposed to urological haematuria, because
Initial investigations for patients with symptomatic non-visible haematuria and persistent asymptomatic non-visible haematuria Measure plasma creatinine and estimated glomerular filtration rate Measure proteinuria-send a random sample of urine for protein:creatinine ratio or albumin:creatinine ratio (according to local practice). Twenty four hour urine collections for protein are rarely needed-24 hour urine protein or albumin excretion (in mg) can be approximated by multiplying the ratio (in mg/mmol) by 10
Measure blood pressure many patients with negative urological investigations do not have a renal biopsy. However, the most common causes are IgA nephropathy and thin membrane nephropathy.
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How common is non-visible haematuria and should testing for haematuria be performed routinely? Non-visible haematuria is present in about 2.5% of the general population, although it can be as high as 20%, depending on features of the study population, such as age, sex, the presence of risk factors for disease, and the definition used. [12] [13] [14] Within cohorts of patients with asymptomatic non-visible haematuria detected by screening, the overall incidence of serious conditions such as urological malignancy is <1.5%, 12 so the consensus is that population screening is not warranted. In contrast, a cause for nonvisible haematuria is found in about 15% of cases selected for referral from primary care to haematuria clinics. 9 10 These cases will usually have had an indication for urine testing, such as urinary tract symptoms. 15 There is currently no evidence to support opportunistic testing for haematuria without a clinical reason.
How should we test for non-visible haematuria in primary care? Urine dipstick Chemical dipsticks detect haem (intact red cells, free haemoglobin, or free myoglobin); they provide an instant result and are used to detect non-visible haematuria in primary care. 10 Chemical dipsticks are available from several manufacturers and are read visually or using automated systems on a semi-quantitative scale. Although it is difficult to interpret studies on the efficiency of this test because of inherent design and reporting bias, analysis of pooled data sets indicates that it is a reasonable way to detect non-visible haematuria in primary care (positive likelihood ratio 5.99 (95% confidence interval 4.04 to 8.89), negative likelihood ratio 0.21 (0.17 to 0.26)). 1 The detection of trace haematuria can be considered negative because the threshold for significance is probably less than three to five red blood cells per high power field. 16 A positive result in a haemolysed sample should be treated the same as in a nonhaemolysed sample because we have no evidence that the clinical relevance differs.
Urine microscopy Red blood cell counts have been used to define microscopic haematuria, and cut-off points have varied (including ≥2 cells per high power field and ≥5 cells per high power field). 17 18 Microscopy provides an accurate measure of red blood cells when assessed by trained technicians or nephrologists in fresh voided early morning midstream specimens of urine. 19 20 However, time to analysis affects the integrity of red blood cells. 21 In a prospective multicentre study, red blood cell counts dropped by 5-9% at five hours, 11-28% at 24 hours, and 29-35% at 72 hours. 22 Because immediate microscopy is not feasible in primary care, the accuracy of quantitative red blood cell microscopy is questionable. In general practice, it is therefore not logical, and rarely necessary, to validate dipstick haematuria by urine microscopy.
How can glomerular haematuria be distinguished from urinary tract haematuria? Urine microscopy for red cell morphology and casts The detection of red cell casts is virtually pathognomonic for a glomerular pathology. Casts are fragile, In patients with asymptomatic non-visible haematuria confirm persistence of blood in at least two out of three dipstick tests It is not necessary to confirm the dipstick result by microscopy
SOURCES AND SELECTION CRITERIA
We drew on evidence published in the systematic reviews of the National Institute for Health and Clinical Excellence, Health Technology Assessment (microscopic haematuria), 1 and guidelines for the early diagnosis and management of chronic kidney disease. 1 2 We searched electronic databases, including Medline and the Cochrane database, to identify recent publications and studies that were deemed relevant but outside the inclusion criteria of the systematic review. We included the evidence presented in published guidelines for the investigation of haematuria published by the American Urological Association and the Scottish Intercollegiate Guidelines Network.
however, and can be very rare or absent even when glomerular disease is present. The test therefore has low sensitivity, particularly for routine samples sent from primary or secondary care clinics to the laboratory.
The relevance of dysmorphic red cells as indicators of glomerular disease is unclear. Samples often contain a mixture of isomorphic (normal shaped) and dysmorphic cells, and the term dysmorphic includes cells with a variety of different shapes. In an observational study to evaluate urinary particles, the presence of acanthocytes (erythrocytes with ring form blebs) was significantly associated with glomerular disease, but other shapes did not distinguish renal disease from urological disease. 23 Urine microscopy relies on the examination of fresh urine by a skilled person and is most useful in specialist clinics rather than as a screening test in primary care.
Proteinuria
Proteinuria is a marker of glomerular damage, particularly as the amount of protein increases (low amounts can result from tubular disease or dysfunction). The presence of proteinuria and haematuria increases the likelihood that the underlying disease is glomerular and is an indication for a referral to the nephrology department. 24 The threshold for significant proteinuria in the presence of non-visible haematuria is 0.5 g/d and equivalent to a protein: creatinine ratio ≥50 mg/mmol or albumin:creatinine ratio ≥30 mg/mmol (NICE guidelines).
Hypertension
Renal disease is strongly associated with hypertension, 25 and it must be considered in patients with hypertension and non-visible haematuria. However, the prevalence of essential hypertension increases with age and hypertension is often an unrelated comorbidity. 26 It is of most discriminatory use in people under 40, where the prevalence of hypertension is low, as is the risk of urological malignancy. 9 10 Do anticoagulants and antiplatelet agents cause haematuria? Visible haematuria in patients taking warfarin or aspirin is caused by underlying pathology in up to 25% of cases. 27 Few detailed studies have assessed non-visible haematuria in patients taking these drugs. In a subgroup analysis of a prospective randomised trial to determine the effects of warfarin and aspirin on the heart, non-visible haematuria was detected in about 10% of patients taking the drugs, and an underlying cause including bladder cancer was detected in 10% of cases. 28 Although not adjusted for age and other risk factors, the incidence of nonvisible haematuria in anticoagulated patients is similar to non-anticoagulated patients, and bleeding cannot be attributed solely to these agents.
What level of non-visible haematuria warrants further investigation?
The term non-visible haematuria best describes a clinical entity and avoids the uncertainties of either Chronic lead or mercury poisoning microscopic or dipstick test definitions. We define symptomatic non-visible haematuria as haematuria in patients with voiding lower urinary tract symptoms-hesitancy, frequency, urgency, dysuria, and loin or suprapubic pain in the absence of a transient cause such as urinary tract infection. A single symptomatic episode should prompt further assessment-in these patients serious pathology is more likely to be present and may cause intermittent bleeding. Asymptomatic non-visible haematuria is haematuria in the absence of these symptoms. When incidental haematuria is detected in asymptomatic patients it must be confirmed as persistent in two of three isolated dipstick tests assessed at an interval of two to three weeks. Patients with asymptomatic disease are least likely to have an underlying urological condition, especially if they are under 40 years. Who should patients be referred to? Primary referral A urological cause is more likely in patients with either visible haematuria or symptomatic nonvisible haematuria, whatever their age, and all those with symptomatic non-visible haematuria aged 40 or more. 9 10 In all these cases, initial referral to urology is important to exclude malignancy. An exception is young adults who present with cola coloured (rather than red or pink) urine, particularly after a respiratory tract infection, who are more likely to have acute glomerulonephritis than urological disease.
Patients under 40 with asymptomatic non-visible haematuria are more likely to have renal rather than urological disease, particularly IgA nephropathy or thin membrane disease. 11 A urology referral is unnecessary in such patients, and a specialist nephrology opinion is often not required either. A definitive diagnosis requires renal biopsy, and unless the management of the patient would be altered by such a diagnosis, it is hard to justify the associated risks. In patients under 40, only the presence of other risk factors for severe glomerulonephritis should trigger a specialist nephrology assessment, namely: Proteinuria ≥0.5 g/d (albumin:creatinine ratio ≥30 mg/mmol or protein:creatinine ratio ≥50 mg/mmol) Estimated glomerular filtration rate <60 ml/min Hypertension.
Management after negative urological investigations and long term follow-up
If no abnormalities are found on initial assessment, routine urological follow-up is not needed. 29 Patients with haematuria need a nephrological assessment if they have or develop manifestations of kidney disease, namely 24 
:
Evidence of deteriorating renal function (fall in estimated glomerular filtration rate of >5 ml/ min within previous year or >10 ml/min any time within past five years) Chronic kidney disease stage 4 or 5 (estimated glomerular filtration rate <30 ml/min) Proteinuria (≥0.5 g/d). The development or presence of hypertension in people over 40 is not a good discriminator because of the increasing prevalence of essential hypertension with age, although it should be checked routinely.
Persistent non-visible haematuria needs to be followed up, usually in primary care. Important but undiagnosed urological disease may become more apparent through the development of urinary tract symptoms in previously asymptomatic patients or the development of visible haematuria. 29 If haematuria is caused by low grade chronic glomerulonephritis (such as IgA nephropathy), this may progress over time and result in new or increasing proteinuria or worsening renal function (or both). 30 31 Patients should therefore have at least an annual review to check for new symptoms and measure the estimated glomerular filtration rate, urinary protein, and blood pressure. The algorithm (figure) lists criteria for referral or re-referral. The Queen Elizabeth 2 left Southampton for the last time on 11 November 2008, bound for Dubai, where she will be moored on a palm shaped island which is to be built specially for her in her new role as a floating hotel. She worked hard in her life since her launch by Her Majesty on Clydebank in 1967. She travelled almost 6 000 000 nautical miles, the equivalent of 14 trips to the moon and back and more than any other ship ever, with the longest journey of almost 7000 miles non-stop returning from the Falkland Islands after the conflict in 1982. I was the principal medical officer for most of my 18 memorable years. Maritime medicine is a strange mix of general practice, emergency medicine, public health, and occupational and travel medicine with some dentistry and, very rarely, veterinary medicine thrown in. We are outside the comforting environment of a hospital, doing our own lab work and getting every result within 30 minutes with point of care testing.
ADDITIONAL EDUCATIONAL RESOURCES
On the QE2 we could, if required, harvest four units of warm, turgid, whole, fully tested blood (sometimes laced with champagne) from passenger donors within an hour. We had a digital x ray system, and, although we checked our own films, we could get a report back from a consultant within an hour electronically. Surgery wasn't done as emergencies presented to us very early, so most abdominal problems could be dealt with conservatively with intravenous antibiotics. We gave thrombolytic treatment when necessary but declined to carry pregnant ladies after 26 weeks' gestation: the last baby to be delivered on board was in 1989, when such a restriction was not in place. Helicopter evacuation, which everyone tends to think of as a viable option, isn't so easy on the Atlantic as helicopters can only fly out about 200 miles from base. I have used them just 14 times, seven times for passengers and seven for crew.
My 18 years has been a great time of quintessential Britishness at its best and wonderful to be part of-after all, somebody had to go around the world with the passengers, drink the champagne, and eat the caviar. The final evening of 27 November 2008 in Dubai, singing all the songs from Last Night of the Proms before retiring, was astonishingly moving. I am grateful and proud I was part of it. I now move back to Queen Mary 2, having been on her maiden voyage in 2004, but I cherish memories of the most famous ship in the world-the one and only, legendary, and elegant QE2. 
